GPCM
ADVM

Granite Point Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Granite Point Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13,000
Closed -$377K – 87
2016
Q4 		$377K Buy
+13,000
New +$425K 0.3% 66
2016
Q3 		– Sell
-18,654
Closed -$589K – 91
2016
Q2 		$589K Buy
+18,654
New +$843K 0.25% 65

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Granite Point Capital Management's ADVM Position: Q1 2017 in Review

Granite Point Capital Management sold out of Adverum Biotechnologies (ADVM) in Q1 2017, closing a stake of 13,000 shares — an estimated $377K sold.

Granite Point Capital Management first reported a position in ADVM in Q2 2016 and held it in 2 quarters. The position peaked at $589K in Q2 2016. 75 funds tracked by Wall St. Rank hold ADVM as of Q1 2017.

  • Granite Point Capital Management reported no remaining Adverum Biotechnologies position as of Q1 2017 after selling out during the quarter.
  • Granite Point Capital Management sold 13,000 Adverum Biotechnologies shares in Q1 2017, an estimated $377K.
  • Granite Point Capital Management first reported a position in Adverum Biotechnologies in Q2 2016 and held it in 2 quarters.
  • Granite Point Capital Management's Adverum Biotechnologies position peaked at $589K in Q2 2016.
  • 75 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2017.

Based on Granite Point Capital Management's 13F filing for Q1 2017, filed 10 May 2017.